GET DAILY SIGNALSAnixa Biosciences (ANIX) Advances Ovarian CAR-T and Breast Cancer Vaccine Programs
Key Takeaways
- Anixa Biosciences is a clinical-stage biotechnology company focused on treating and preventing cancer through an ovarian cancer CAR-T therapy and a breast cancer vaccine.
- ANIX shares have moved modestly over the past month, rising roughly 4% from about $2.67 to near $2.77, with elevated volatility in late October.
- The company completed dosing of the fifth cohort in its ovarian cancer CAR-T trial and reported preliminary stable disease and multi-year survival observations.
- The breast cancer vaccine completed Phase 1 with all primary endpoints met, with planning for a Phase 2 trial now underway.
- Anixa runs a capital-efficient, partnership-driven model with leading institutions including Cleveland Clinic and Moffitt Cancer Center.
- Investors can find detailed Price Targets, Earnings, and Forecast data on dedicated pages to support further research.
Where ANIX Stands in the Market Right Now
Anixa Biosciences trades in the low single digits, a range typical of development-stage oncology companies. Over the trailing 30-day window, ANIX advanced from approximately $2.67 to around $2.77, a gain of roughly 4%. The stock experienced a notable upswing in late October before giving back some of those gains in early November, reflecting the news-driven, sentiment-sensitive nature of small-cap biotech names. Trading volume has remained moderate, with periodic spikes around clinical and conference announcements.
Broader investor interest in cancer immunotherapy and cancer vaccines has provided a supportive backdrop for the sector, though clinical-stage companies without approved products remain exposed to binary data events and financing considerations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Anixa Biosciences (ANIX) Business Overview and Competitive Position
Anixa Biosciences is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's lead therapeutic candidate is liraltagene autoleucel, or lira-cel, an investigational CAR-T therapy being evaluated in a Phase 1 dose-escalation trial for recurrent ovarian cancer in collaboration with Moffitt Cancer Center. Lira-cel uses chimeric endocrine receptor-T cell (CER-T) technology to target the follicle-stimulating hormone receptor (FSHR), which is expressed on ovarian cancer cells but has limited expression in healthy tissue.
The company's second program is an alpha-lactalbumin breast cancer vaccine developed with Cleveland Clinic and supported in part by funding from the U.S. Department of Defense. The vaccine is designed to treat existing disease as well as reduce the risk of recurrence or initial development. Anixa's broader vaccine platform also targets additional cancer types, including ovarian, lung, colon, and prostate cancers.
Anixa's competitive positioning rests on a capital-efficient model that partners with leading research institutions to advance its pipeline while limiting fixed costs. The company reported approximately $14 million in cash and short-term investments as of July 31, 2026, with no debt.
Recent Developments Driving ANIX
Clinical progress has been the dominant driver of sentiment. Anixa announced completion of treatment of the fifth cohort in its ovarian cancer CAR-T trial, with patients receiving a dose 100-fold higher than the first patient treated. To date, no dose-limiting toxicities have been observed, and the company reported the first patient exhibiting stable disease 90 days after treatment, four patients surviving more than one year, and one patient surviving beyond two years. Management has indicated plans to advance to a sixth cohort with a further tenfold dose increase.
On the vaccine side, the Phase 1 breast cancer trial met all primary endpoints, demonstrating a favorable tolerability profile and protocol-defined immune responses in 74% of participants, with preparations underway for a Phase 2 study. The company also continued to broaden its intellectual property estate, securing patents for the vaccine in Mexico and Australia with protection extending into 2040.
Institutional and insider signals have also drawn attention. H.C. Wainwright maintained a Buy rating on the stock while lowering its price target to $6 from $7, and Chairman and CEO Dr. Amit Kumar purchased 5,000 shares on the open market in late October. The company also announced that its trial's principal investigator will present ovarian cancer CAR-T data at the ESMO Immuno-Oncology & Advanced Therapies Congress in December 2026. From what I see, these updates underscore the execution focus at ANIX.
2026 Outlook and What Investors Should Watch
Several catalysts are likely to shape ANIX in the months ahead. The December 2026 ESMO Immuno-Oncology presentation is a near-term focal point, as it may provide updated safety and preliminary efficacy observations from the ovarian cancer CAR-T trial. Progression toward the sixth dose cohort and any additional survival or response data will be closely watched by investors evaluating the therapy's differentiation.
The breast cancer vaccine's advancement toward a Phase 2 trial represents another key milestone, with trial design and timing expected to influence the program's perceived value. Continued international patent grants and any partnership or licensing activity could also serve as meaningful developments.
As with all clinical-stage biotech companies, investors should monitor cash runway and any financing activity, given the capital required to advance clinical programs. Broader market conditions affecting small-cap biotechnology valuations, as well as regulatory and data readouts across the oncology sector, remain important contextual factors. I’m watching this closely for any shifts in the competitive landscape.
Exploring AI Tools for Biotech Research
In my view, supplementing fundamental analysis with data-driven tools can add useful perspective when evaluating clinical-stage names like ANIX. I’ve used Tickeron’s AI Trading Bots to review automated signals across the sector, which helps highlight patterns without replacing my own due diligence on clinical milestones and capital position.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ANIX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 11, 2026
ANIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 35 cases where ANIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for ANIX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +9.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIX advanced for three days, in 180 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for ANIX moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANIX as a result. In 90 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ANIX turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
ANIX moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ANIX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.627) is normal, around the industry mean (3.498). P/E Ratio (-9.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (384.615) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. ANIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of non-invasive blood tests for the early detection of solid tumor based cancers
Industry Biotechnology
Advertisement